OncoMatch/Clinical Trials/NCT06859190
Efficacy of Auricular Pressure Beans with Electroacupuncture and Estazolam Treating Insomnia Caused by Cancer
Is NCT06859190 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies estazolam 1-2 mg for cancer.
Treatment: estazolam 1-2 mg — The core objectives of this study are to assess the short-term and long-term efficacy of auricular acupoint pressure beans combined with electroacupuncture and estazolam in the treatment of cancer-caused insomnia. The study aims to accurately compare the differences between this combination therapy and standard Western medicine in improving sleep quality and effectively alleviating anxiety and depression. Additionally, it will meticulously observe the safety of the combined treatment and record the occurrence and potential causative factors of any adverse reactions.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: acupuncture or auricular pressure bean therapy
Received acupuncture or auricular pressure bean therapy within the past 3 months.
Cannot have received: insomnia medication
No medications related to the treatment of insomnia have been used in the last 1 month.
Lab requirements
Kidney function
no serious dysfunction
Liver function
no serious dysfunction
Cardiac function
no serious dysfunction
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify